

Chronic pelvic pain syndrome in women. Review and preliminary results with low-energy extracorporeal shock wave therapy

ANDREA MENEGHINI¹, MONICA TREVISAN³, EFTHYMIA LAMPROPOULOU³, NICOLA MENEGHINI²

¹ Padua Teaching Hospital, Advanced Technology in Rehabilitation Lab, Department of Orthopaedic Rehabilitation

² School of Medicine, University of Padua

³ School of Specialization in Physical Medicine and Rehabilitation, Department of Neuroscience, University of Padua

Abstract. Introduction: Chronic Pelvic Pain Syndrome (CPPS) is a highly prevalent and very debilitating clinical condition, with a significant impact on the social, working and family activities, negatively affecting the quality of life. Currently there is not yet an satisfying treatment. Several therapeutic options have been proposed and experimented with some results, but in certain patients they are all ineffective. Extracorporeal Shock Wave Therapy (ESWT) could be a new secure and promising approach for this condition. **Aim of the study:** To describe our experience about the effects of three cases of female CPPS. **Materials and Methods:** Three women suffering from CPPS underwent four weekly sessions ESWT (3000 SW, 3 Hz, 0,25 mJ/mm²) with the aim to reduce their pain. Basal and 2 follow-up assessments were conducted using NRS pain score and recording the consumption of medications. **Results:** In one case we observed a partial improvement on pain, in the second one no benefit and in the last one an almost complete disappearance of the pain. No adverse events were registered. **Discussion and Conclusions:** Although our result are discordant, Low-energy ESWT could represent a new promising treatment for CPPS as it is simple, non-invasive, painless, well tolerated, apparently secure, but more studies are needed to discover the mechanisms through which ESWT acts on the pain and to define the optimal parameters and the better approach to use in clinical practice.

Keywords: Woman's pelvic pain; Chronic pelvic pain syndrome; ESWT; Shock wave therapy; Quality of life.

INTRODUCTION

Chronic pelvic pain Syndrome (CPPS) is a highly prevalent condition which can present a major challenge to health care providers due to its complex aetiology and poor response to therapy.^{1,2} Much of the research examining chronic or recurrent pelvic pain in women has been hampered by the lack of a consistent definition.²

CPPS is a very debilitating clinical condition with a significant impact on the social, working and family activities, negatively affecting the quality of life.

There is a great variability of prevalence in literature,³ from 2.1^{4,5} to 43.4%,⁶ due to the definition used, the characteristics and quality of the studies and the cultural characteristics of the population studied.

Pelvic pain is an understated and major problem. The best available figures suggest the number of women in the UK with chronic pelvic pain as 1 million (compared with 1.6 million adults with low back pain).⁷ CPPS is the reason of 10% outpatient gynaecological visits, 40% diagnostic laparoscopy and 10-15% hysterectomy in the USA⁸. Amongst males, CPPS can affect 10%-15% of the population and results in nearly 2 million outpatient visits each year.⁹

Diseases characterized by pain have a documented higher prevalence in females.^{10,11} In particular abdominal and perineal pain syndromes are sharply more frequent among women, because of anatomy, hormonal conditions, and reproductively aspects.¹² Besides epidemiological studies have shown differences between women and men's pain perception.¹⁰

TERMINOLOGY AND DEFINITIONS

The International Association for the Study of Pain (IASP) defined pain as "an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage".^{13,14}

Definitions and classifications of *chronic pelvic pain* (CPP) have evolved from the mid-1990s under the thrust of

expert groups and scientific societies involved on this type of pain. Indeed, classic definitions and classifications were based on the notion of organ disease and usual medical process (infectious, inflammatory, metabolic) and did not allow a proper understanding of functional pathologies.¹⁵

Apte G et al.¹⁶ define *pelvic pain* as pain arising from the visceral or somatic system and encompasses structures supplied by the nervous tissue from the 10th thoracic spinal level and below. When this pain is recurrent or persistent and associated with symptoms, suggesting involvement of the musculoskeletal, gynecological, urological or gastrointestinal systems and the absence of inflammation or other specific pathology we have a *pelvic pain syndrome*, while *chronic pelvic pain* (CPP) is defined as non-malignant pain perceived in the structures related to the pelvis that has been present for more than 6 months or has a non-acute pain mechanism of shorter duration.¹⁶

The definition of a chronic pelvic pain theoretically assumes that three components are present: the same pain, its chronic character and pelvic-perineal topography. Nevertheless the definition is more complex and overcomes these three aspects because chronic pain is not only a symptom based on a notion of duration but a syndrome associating various conditions, the chronic pain syndrome.¹⁵

More recently the European Association of Urology has defined *chronic pelvic pain* as chronic or persistent pain perceived in structures related to the pelvis of either man or woman, that is often associated with negative cognitive, behavioral, sexual and emotional consequences as well as with symptoms suggestive of lower urinary tract, sexual, bowel, pelvic floor or gynecological dysfunction.

CPP is a frequent and difficult problem because, despite the quality and diversity of diagnostic procedures, no relevant aetiology will be found in 30 to 40 % of all cases.¹⁷

Indeed chronic pelvic pain may be subdivided into "*specific disease-associated pelvic pain*", if it is related to a well-defined classical pathology (such as infection or cancer) and "*chronic pelvic pain syndrome*" when it is not associated to an obvious pathology. Hence CPPS is the occurrence of CPP,

often associated with negative cognitive, behavioral, sexual or emotional consequences (depression, anxiety, fears about pain or its implications, unhelpful coping strategies, and distress in relationships, catastrophic interpretation of pain, sense of helplessness), as well as with symptoms suggestive of lower urinary tract, sexual, bowel or gynaecological dysfunction, in the absence of proven infection or other obvious local pathology that may account for the pain.¹

Confusingly, a patient may have a well-defined pelvic condition concurrently with chronic pelvic pain syndrome.^{7,18}

Pain perception in CPPS may be focused within a single organ, more than one pelvic organ and even associated with systemic symptoms such as chronic fatigue syndrome (CFS), fibromyalgia (FM) or Sjögren's syndrome. When the pain is localised to a single organ, some specialists may wish to consider using an endorgan term such as prostate pain syndrome, bladder pain syndrome, urethral pain syndrome, chronic anal pain syndrome. When the pain is localised to

more than one organ site, the term CPPS should be used.

As more information is collected suggesting that the CNS is involved, and indeed may be the main cause of many CPP conditions (e.g., bladder, genitalia, colorectal or myofascial), there is a general tendency to move away from end-organ nomenclature.

Perineal pain syndrome should be mentioned: it is a neuropathic-type pain that is perceived in the distribution area of the pudendal nerve, and may be associated with symptoms and signs of rectal, urinary tract or sexual dysfunction; in this condition there is no proven obvious pathology. It should be distinguished from pudendal neuralgia which is a specific disease associated with pelvic pain that is caused by nerve damage.¹

We report below (Table 1) the EAU classification of chronic pelvic pain syndromes,¹ set up according to the axis system used by IASP; it may be a useful tool for clinical purpose:

TABLE 1. – The EAU classification of chronic pelvic pain syndromes.

Axis I Region		Axis II System	Axis III End-organ as pain syndrome as identified from Hx, Ex, Ix	Axis IV Referral characteristics	Axis V Temporal characteristics	Axis VI Character	Axis VII Associated symptoms	Axis VIII Psychological symptoms											
Chronic Pelvic Pain	Specific disease associated pelvic pain	Urological	Prostate	Suprapubic	ONSET	Aching Burning Stabbing Electric	UROLOGICAL	ANXIETY											
			Bladder	Inguinal	Acute														
			Scrotal	Urethral	Chronic														
			Testicular	Penile/ clitoral	ONGOING														
			Epididymal	Perineal	Sporadic														
	OR Pelvic Pain Syndrome	Gynaecological	Penile Urethral	Rectal	Cyclical				TIME	Dysfunctional flow Urge Incontinence	Gynaecological								
			Post- vasectomy	Back	Continuous														
			Vulvar	Buttocks	Emptying														
			Vestibular	Thighs	Filling														
			Clitoral		Immediate														
Gastrointestinal	Endometriosis associated			post	Late post TRIGGER	Menstrual Menopause	GASTROINTESTINAL												
		CPPS with cyclical exacerbation																	
		Dysmenorrh- oea																	
Peripheral nerves	Irritable bowel	Chronic anal						Provoked Spontaneous				Constipation Diarrhoea Bloatedness Urge Incontinence	NEUROLOGICAL						
		Intermittent chronic anal																	
Sexological	Chronic anal	Pudendal pain syndrome							Hyperaesthesia Allodynia Hyperalgesia	Sexual avoidance Erectile dysfunction	SEXUOLOGICAL								
		Pelvic pain with sexual dysfunction																	
Psychological	Any pelvic organ													Satisfaction Female dyspareunia Sexual avoidance	Medication	MUSCLE			
Musculo- skeletal	Pelvic floor muscle Abdominal muscle Spinal																Function impairment	Fasciculation	CUTANEOUS
		Coccyx			Trophic changes Sensory changes	Avoidance	SYMPTOMS												




Figure 1. – Algorithm for the diagnosis and treatment of CPP:⁴⁶ DRE = digital rectal examination; PSA = prostate-specific antigen; US = ultrasound; PFM = pelvic floor muscle; TRUS = transrectal ultrasound.

Physiopathology of CPPS

Pain in the pelvic region can arise from musculoskeletal, gynecologic, urologic, gastrointestinal, and/or neurological conditions. Such pain can involve both the somatic (T12-S5) and visceral (T10-S5) systems, making the differential diagnosing challenging.¹⁶

CPP mechanism may involve:

1. Ongoing acute pain mechanisms¹⁹ (such as those associated with inflammation or infection), which may involve somatic or visceral tissue.
2. Chronic pain mechanisms, which especially involve the central nervous system.^{20,21}
3. Emotional, cognitive, behavioural and sexual responses and mechanisms.²²⁻²⁵

In most cases of CPP, ongoing tissue trauma, inflammation or infection is not present.²⁶⁻²⁹ However, recurrent trauma, infection or ongoing inflammation may result in CPP in a small proportion of cases. For this reason the early stages of assessment include looking for these pathologies.³⁰

A nociceptive event activates acute pain mechanisms (direct activation of the peripheral nociceptor transducers), but could also generate a sensitisation of the nociceptor transducers, thus magnifying the afferent signalling. There may be activation of the so-called silent afferents. The increased afferent signalling is often a trigger for the chronic pain mechanisms that maintain the perception of pain in the absence of ongoing peripheral pathology.^{31,32}

Possible mechanisms by which the peripheral transducers may exhibit an increase in sensibility are:

1. modification of the peripheral tissue, so the transducers become more exposed to peripheral stimulation;
2. increase in the chemicals that stimulate the receptors of the transducers;³³
3. modifications in the receptors that make them more sensitive.

In general, the first two mechanism lower the threshold of activation of transducers, the third one increases responsiveness to external stimuli.¹

At the spinal level three processes are involved in central sensitization:

- Changes in existing protein activity (post-translational processing);
- changes in genetic transcription of proteins;
- structural changes in neuron connectivity.

The first process is the earliest (within minutes); the latter two processes may occur within days.^{34,35}

The result is that a stimulus produces a magnified evoked response in these neurons.¹

CPPS is probably manifested as a myofascial pain syndrome with an abnormal tone of the pelvic floor muscles, and a neurological component has become increasingly apparent, associated with dysfunctional effects.^{36,37,38} Myofascial dysfunction of the pelvic floor has been implicated in CPP conditions as both a causative and associated factor responsible for pain.³⁶⁻⁴⁰

Many of the complaints are closely connected to the autonomous nervous system, and the interplay between smooth and cross-striated muscles. Acute and chronic inflammations occurring via the sympathetic endplate might be involved, leading to the endogenous generation of pain via nociceptive nerve endings and receptors. Certain kinds of psychological stress can lead to abnormal electromyographic activity and to myofascial pain syndromes.⁴¹

Anymore, in the pain syndromes, the role of the nervous system in generating the sensations is thought to be pivotal, but the term “syndrome” indicates that, although peripheral mechanisms may exist, CNS neuromodulation may be more important and systemic associations may occur; “syndrome”



Figure 2. – Duolith SD1 Storz Medical.

takes into account the emotional, cognitive, behavioural, sexual and functional consequences of the chronic pain.¹

Diagnosis of CPPS

Diagnosis of CPPS is based on symptoms and on exclusion of obvious diseases than could cause pain.⁴²

The presenting symptoms for many of the known causes of chronic pelvic pain (CPP) are often similar and non-specific, making it difficult to differentiate between causes.^{1,2} Chronic infection, inflammation, neuropathy, pelvic floor muscle dysfunction, autoimmune disease, and neurobehavioral disorders are among the postulated etiologies, although no single factor is thought to be the cause.⁴³

At any rate, to identify the cause of dysfunction, a systematic approach to examination is essential. Such an approach provides the practitioner the best ability to: (1) appraise relevant historical findings; (2) clinically examine their patients by anatomical region; (3) identify specific mechanical and motor control dysfunctions; (4) determine the level of nervous system sensitization; and (5) evaluate the extent of biopsychosocial involvement in the patient's condition.¹⁶

While the history may indicate pain from a pelvic source, consideration for referred pain from structures outside the pelvic region should not be overlooked.^{1,44}

System investigations should be guided by the medical history and examination to exclude and/or identify end organ pathology.⁴⁵ Laboratory, imaging, neurophysiological studies, endoscopy and laparoscopy can help the physician to make a diagnosis.⁴⁶

Fall et al.⁴⁶ proposed an algorithm for diagnosis and management of chronic pelvic pain (Figure 1).

Treatment of CPPS

Various drugs are used individually and in various combinations to reduce pain and improve quality of life in patients with CPPS:^{1,46} simple analgesics and NSAIDs, opioids, antidepressants, anticonvulsants, antibiotics, α -receptor blockers, and 5 α -reductase inhibitors (5-ARIs). A certain group of patients may benefit from these therapies, but often side-effects may predominate over possible treatment effects, thus minimising the benefit to the patient.^{46,47} Other therapeutic options are represented by nerve blocks. Sacral neuromodulation, Botulinum toxin, TENS, triggerpoints' massage, electromagnetic treatment, acupuncture, cognitive behavioural therapy, and biofeedback and relaxation training, hyperthermia, and phytotherapy.^{43,46,47}

In the latest years some studies have proposed ESWT for treatment of CPPS.^{43,47,48,49,50}

Low-energy ESWT could affect CPPS by several mechanisms, such as reducing passive muscle tone, hyperstimulating nociceptors, interrupting the flow of nerve impulses, or influencing the neuroplasticity of the pain memory. Human data for the indication of CPPS are not available for any of these mechanisms. The number of shock waves and the energy level chosen were purely empirical, and many technical questions (eg. the impact of prostate volume) remain unanswered.^{47,49}

Despite this limits, this approach might represent an advance in the treatment of CPPS, thanks to its benefits: the possibility of outpatient execution, no need for anaesthesia, lack of side-effects, easy repeatability.⁴⁷

ESWT-associated pain alleviation based on hyperstimulation of nociceptors was intended to interrupt the flow of nerve impulses.^{51,52} Furthermore, ESWT-induced revascularization processes can alleviate pain and help to heal tissue.^{47,53} The stimulation of microvascularization and reduction in muscle tone after applying SWs is demonstrated.⁵⁴

ESWT possibly influence the neuroplasticity of the 'pain memory'.⁴⁸ The prolonged lack of effective pain therapy could lead to a reinforcement of negative impulses (pain) in the brain. Long-term fixation of these impulses could result in the development of a particular pain memory. By minimal pain impulses, ESWT could break through this negative-conditioned pain memory and induce a sort of "reprogramming", resetting the pain.⁵⁵ This theory might explain, for example, why it is possible to influence an area of pain located some distance from the treatment locus.^{47,48}

The periprosthetic pelvic floor muscles are also influenced by the therapy, therefore local muscle relaxation could be causing the disorder improving as the result of a reduction in functional muscle shortening.

Zimmerman et al. supported the hypothesis that the underlying effective mechanisms are not just local alterations, but associated with many factors, because the pain reduction by SWs remained effective over a period of several weeks.⁴⁷

PATIENTS AND METHODS

We treated three women suffering from CPPS with four weekly sessions ESWT with the aim to reduce their pain (all three patients reported a pain intensity 9/10 at NRS). After giving to each patient detailed information about potential benefits and risks of the procedure, treatment was conducted using a standard electromagnetic SW device (DUOLITH SD1, Storz Medical Tägerwil, Switzerland) (Figure 2), following a protocol based on literature parameters: 3000 focused shock waves, frequency 3 Hz, energy level 0,25 mJ/mm².⁴⁷ Follow-up assessment was carried out one week and eight months after treatment.

All three patients had already tried several common treatment (drugs, infiltrations, anesthetic blockade, sacral neuromodulation, dilatation, acupuncture, supplements) before coming to our attention. Other information about these patients is reported below:

S.M.A., 49 years-old, BMI 23,1, previous appendicectomy, sphincterotomy for anal fissure complicated by abscess, two vaginal deliveries (the first with episiotomy, the second with lacerations), normal intestinal function, regular menstrual cycle. Reported symptoms: intense anal and gluteal pain, lasting for 6 years, absent at night and increasing during the course of the day, worsening during menstrual cycle, associated with anal pricking, daily rectal tenes-

mus and anxiety. Physical examination, in particular rectal exploration, pointed out tenderness in the region between anus and right ischiatic spine and in correspondence of tendineous centre of perineum. No abdominal, genital and anal alterations were found at physical examination, anoscopy and sigmoidoscopy, except for scars of previous surgery.

P.G., 69 years-old, BMI 18,3, regular intestinal function, previous colectomy, surgery for anal fissure, exeresis of an anal polipo, a vaginal delivery, hysterectomy and ovariectomy. Reported symptoms: chronic intense bruising anal pain (mostly during defecation), associated with rectal tenesmus and anxiety.

Physical examination revealed abdominal bloating, painful trigger points of the levator ani, no other perineal, anal, genital abnormalities.

M.Z., 60 years-old, BMI 20,3, regular intestinal function, two vaginal delivery (both with episiotomy), dysmenorrhoea before the first pregnancy, previous appendicectomy, hysterectomy for endometriosis, surgical treatment for crural hernia, exeresis mammary nodule, exeresis pulmonary hamartoma, osteoporosis, laminectomy for lumbar stenosis (L4-L5). Reported symptoms: intense bruising anal and low-back pain, associated with pollachiuria, urgency, vesical tenesmus (rare rectal tenesmus), intestinal bloating, flatulence, anxiety. Physical examination showed abdominal bloating, tenderness in correspondence of coccyx and ischiatic spine, vulvar and vestibular pain, no other perineal, anal, genital abnormalities.

In literature, all studies on ESWT in CPPS describe a perineal approach (patients were supine and the probe was positioned on the perineum). Indeed, we wanted to try a new approach: patients were positioned in lateral decubitus and the probe on the most painful point for half treatment (1500 SW) and then on the gluteal region (at the emergence of pudendal nerve from pelvis both in left then in right part) for the second half treatment (1500 SW), with the intent to interfere with the pudendal nerve transmission.

The pudendal nerve comprises the anterior branches of the ventral rami from S2 to S4. It exits the pelvis through the greater sciatic foramen and reenters the pelvis through the lesser sciatic foramen, passing between the sacrospinous ligament anteriorly and sacrotuberous ligament posteriorly, while wrapping behind the ischial spine. Once in the perineal area, the pudendal nerve travels within the Alcock's (pudendal) canal, a tunnel created by the overlying parietal fascia covering the obturator muscle. The nerve is accompanied by the pudendal artery and vein, and nerve to the obturator internus through the pudendal canal. The pudendal canal is located on the medial aspect of the obturator internus covered by the obturator fascia. Once the nerve reenters the pelvis it divides into three branches that are named for the structures they innervate.

The first branch of the pudendal nerve, the nerve to the levator ani, arises just proximal to the pudendal canal and supplies motor function to the external anal sphincter and perianal skin. The second branch, also known as the perineal branch, provides sensation to the perineal skin, vaginal tissues, and vestibule, as well as motor fibers to the external urethral sphincter. The third branch innervates the anal sphincters. The pudendal nerve provides sensory innervation to an area defined by the inferior pubic ramus, labio-crural folds, and the intergluteal fold. The pudendal nerve converges on the area of the dorsal horn shared with the cervix, uterosacral, and vulvovaginal area. The pudendal nerve is a mixed sensory and motor nerve, often leading to concurrent motor and sensory symptoms.¹⁶

RESULTS

In the first case NRS before ESWT was 9/10; at one-week follow up was 9/10; at the 8 months follow-up it was variable from 5/10 (during the day) to 8/10 (in the evening). It was referred that, although pain was intense at certain times of the day, no analgesic drugs were taken.

In the second case NRS before ESWT was 9/10 and did not change at the follow-up assessments. Pharmacological therapy remained the same compared to before treatment.

In the third case NRS before therapy was 9/10 and gradually decreased during the treatment; at one week follow-up NRS was 2/10 and kept the same at 8 months, with no need to assume analgesic drugs.

No adverse effects occurred altogether.

DISCUSSION

Chronic pelvic pain (CPP) is a highly prevalent and debilitating clinical condition with a significant impact on the social, working and family activities of women, negatively affecting their quality of life.

Identifying the pain generators and effectively treating this condition is a formidable challenge and this explains the tendency for pelvic pain to become chronic.¹ Numerous patients face frustration from the inadequate effects of treatment following multiple repeated attempts to cure this disorder. Recently, multi-modal treatment approaches and the utilization of complementary and alternative medicine (CAM) strategies have been suggested as potential treatment options for CP/CPPS.⁴³

Some recent studies have suggested the potential role of ESWT within the therapeutic pathway for CPPS. Actually five studies^{43,47,48,49,50} on male and just one⁵⁶ on female CPPS have been issued in literature. The authors reported promising results of this kind of treatment, with an important reduction of pain and an improved quality of life.

In our experience three women with CPPS have been treated with ESWT, using parameters based on Vahdatpour's work (4 sessions, 3000 SW, 3 Hz, 0,25 mJ/mm²).⁵⁰ All three women suffered from intense pain (NRS score pre-treatment 9/10). According to literature, no pain or discomfort was felt by patients (no anaesthesia was required), and no apparent side-effects or complications occurred, suggesting that this therapy is painless, secure and well tolerated.

Results at follow-up assessment were different between the three patients: the first one reported a partial pain reduction (as demonstrated by lower NRS score in some hours of the day and suspension of pharmacologic therapy), the second one had no effect from ESWT, while the third one obtained an important improvement of her pain (NRS score post-treatment 2/10).

It would take a wider sample to obtain meaningful data, just three cases are too few. Thus we formulated some assumptions about the possible reasons of such different effects: the pain in the three patients could have a different origin and mechanism (let think about the variability in patients' histories), therefore a same therapy could be effective in some cases but not in other; the parameters used (determined empirically) were maybe inadequate for at least one of the three patients, that means that therapy should be customized on patient; besides 4 sessions could be too few to obtain a significant result, in fact in other experiences until 11 sessions were given; the original transgluteal approach, that was thought to have the effect of modulate the transmission of the pudendal nerve, could be more effective than the classic perineal one in some patients but not in all of them, probably because in "non-responders" the pudendal nerve is not heavily involved in the pain mechanisms,

but pain originates in other anatomical structures, such as muscles or bowels.

CONCLUSIONS

CPPS is a frequent condition, often associated with negative cognitive, behavioral, sexual or emotional consequences, compromising the quality of life. Between various therapeutic approaches, most of the time ineffective, ESWT represents a new promising treatment for CPPS: it is simple (it is an outpatient procedure), non-invasive, painless (it does not require anaesthesia), well tolerated, apparently secure. Although our results are discordant, some studies in literature report benefits of this treatment in patients with CPPS (both males and females). It means that some effect of ESWT on CPPS exists, but more studies are needed to discover the mechanisms through which ESWT acts on the pain and to define the optimal parameters and the better approach to use in clinical practice

DISCLOSURES

The Authors declare that there are no conflicts of interest.

This research received no grant from any funding agency in the public, commercial or not-for-profit sectors.

REFERENCES

- Engeler D, Baranowski AP, Borovicka J, Cottrell A, Dinis-Oliveira P, Elneil S, Hughes J, Messelink EJ, Van Ophoven A, Reisman Y, Williams AC de C. Guidelines on Chronic Pelvic Pain. European Association of Urology 2014.
- Dick ML. Chronic pelvic pain in women: assessment and management. *Aust Fam Physician*. 2004 Dec; 33(12):971-6.
- Latthe P, Latthe M, Say L, Gulmezoglu M, Khan KS. WHO systematic review of prevalence of chronic pelvic pain: a neglected reproductive health morbidity. *BMC Public Health*. 2006; 6:177. doi: 10.1186/1471-2458-6-177.
- Rulin MC, Davidson AR, Philliber SG, Graves WL, Cushman LF. Long-term effect of tubal sterilization on menstrual indices and pelvic pain. *Obstet Gynecol*. 1993; 82: 118-121.
- Zondervan KT, Yudkin PL, Vessey MP, Dawes MG, Barlow DH, Kennedy SH. Prevalence and incidence of chronic pelvic pain in primary care: evidence from a national general practice database. *Br J Obstet Gynaecol*. 1999; 106: 1149-1155. doi: 10.1111/j.1471-0528.1999.tb08140.x.
- Zondervan KT, Yudkin PL, Vessey MP, Jenkinson CP, Dawes MG, Barlow DH, et al. The community prevalence of chronic pelvic pain in women and associated illness behaviour. *Br J Gen Pract*. 2001; 51: 541-547
- Baranowski AP, Lee J, Price C and Hughes J. Pelvic pain: a pathway for care developed for both men and women by the British Pain Society. *Br J Anaesth* 2014; 112(3): 452-9.
- Gelbaya TA, Bch MB, El-Halwagy HE. Focus on primary care: chronic pelvic pain in women CME review article. *Obstetrical and Gynecological Survey*, 2001; 56; 12: 757-763.
- Murphy AB, Macejko A, Taylor A, Nadler RB. Chronic prostatitis management strategies. *Drugs*. 2009; 69: 71-84.
- Unruh AM. Gender variations in clinical pain experience. *Pain* 1996; 65: 123-167.
- Berkley KJ. Sex differences in pain. *Behavioural and Brain Sciences* 1997; 20: 371-380.
- Berkley KJ, Holdcroft A. Sex and gender differences in pain. In: Wall PD e Melzack R (eds) *Textbook of pain*. Churchill Livingstone, Edinburgh 1999; cap 41, pp. 951-965.
- Anon. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. *Pain Suppl* 1986; 3:221-6.
- Anon. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. In: Merskey H, Bogduk N, editors. *Task force on taxonomy. International association for the study of pain*. 2nd ed. Seattle: IASP Press; 1994.

15. Delavierre D, Rigaud J, Sibert L, Labat JJ. Definitions, classifications and terminology of chronic pelvic and perineal pain. *Progrès en urologie* 2010; 20: 853-864.
16. Apte G, Nelson P, Brismé JM, Dedrick G, Justiz RIII, Sizer PS Jr., Chronic Female Pelvic Pain-Part 1: Clinical Pathoanatomy and Examination of the Pelvic Region. *Pain Practice*, Volume 12, Issue 2, 2012 88–110. doi: 10.1111/j.1533-2500.2011.00465.x. Epub 2011 May 26.
17. Dellenbach P, Rempp Ch, Haeringer M Th, Simon Th, Magnier F, Meyer Ch. Douleur pelvienne chronique: diagnostic et traitement. *Gynécologie Obstétrique Fertilité* 2001; 29: 234-43
18. RCOG. The Initial Management of Chronic Pelvic Pain. Ed2 Green Top 41. London: Royal College of Obstetricians and Gynaecologists, 2012.
19. Linley JE, Rose K, Ooi L, et al. Understanding inflammatory pain: ion channels contributing to acute and chronic nociception. *Pflugers Arch*. 2010 Apr; 459(5): 657-69.
20. Serap Kaya, Linda Hermans, Tine Willems, Nathalie Roussel and Mira Meeus, Central Sensitization In Urogynecological Chronic Pelvic Pain: A Systematic Literature Review. *Pain Physician* 2013; 16: 291-308. ISSN 1533-3159.
21. McMahon SB, Dmitrieva N, Koltzenburg M, et al. Visceral pain. *Br J Anaesth* 1995 Aug;75(2):132-144.
22. Bergeron S, Khalifé S, Glazer HI, et al. Surgical and behavioral treatments for vestibulodynia: two-and one-half year follow-up and predictors of outcome. *Obstet Gynecol*. 2008 Jan;111(1): 159-66.
23. Tripp DA, Nickel JC, Wang Y, et al. Catastrophizing and pain-contingent rest predict patient adjustment in men with chronic prostatitis/chronic pelvic pain syndrome. *J Pain* 2006 Oct; 7(10): 697-708.
24. Tripp DA, Nickel JC, Fitzgerald MP, et al. Sexual functioning, catastrophizing, depression, and pain, as predictors of quality of life in women with interstitial cystitis/painful bladder syndrome. *Urology*. 2009 May; 73(5): 987-92.
25. Nickel JC, Tripp DA, Pontari M, et al. Psychosocial phenotyping in women with interstitial cystitis/painful bladder syndrome: a case control study. *J Urol* 2010 Jan; 183(1): 167-72.
26. Abrams PA, Baranowski AP, Berger RE, et al. A new classification is needed for pelvic pain syndromes--are existing terminologies of spurious diagnostic authority bad for patients? *J Urol* 2006 Jun; 175(6): 1989-90.
27. Baranowski AP, Abrams P, Berger RE, et al. Urogenital pain--time to accept a new approach to phenotyping and, as a consequence, management. *Eur Urol* 2008 Jan; 53(1): 33-6.
28. Baranowski AP, Abrams P, et al. (2008). *Urogenital Pain in Clinical Practice*. New York, Informa Healthcare.
29. Hanno P, Lin A, Nordling J, et al. Bladder Pain Syndrome Committee of the International Consultation on Incontinence. *Neurourol Urodyn* 2010; 29(1): 191-198.
30. van de Merwe JP, Nordling J, Bouchelouche P, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. *Eur Urol* 2008 Jan; 53(1): 60-7.
31. Wesselmann U, Baranowski AP, Börjesson M, et al. Emerging therapies and novel approaches to visceral pain. *Drug Discov Today Ther Strateg*. 2009 Fall; 6(3): 89-95.
32. Giamberardino MA, Costantini R, Affaitati G, et al. Viscero-visceral hyperalgesia: characterization in different clinical models. *Pain*. 2010 Nov; 151(2): 307-22.
33. Cervero F, Laird JM. Understanding the signaling and transmission of visceral nociceptive events. *J Neurobiol*. 2004 Oct; 61(1): 45-54.
34. Nazif O, Teichman JM, Gebhart GF, et al. Neural upregulation in interstitial cystitis. *Urology*. 2007 Apr;69(4 Suppl):24-33.
35. Merskey H, Bogduk N. *Classification of Chronic Pain*. Seattle, IASP press.
36. Oyama IA, Rejba A, Lukban JC, et al. Modified Thiele massage as therapeutic intervention for female patients with interstitial cystitis and high-tone pelvic floor dysfunction. *Urology*. 2004; 64: 862-865.
37. Karin E, Westesson & Daniel A. Shoskes Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Pelvic Floor Spasm: Can We Diagnose and Treat? *Curr Urol Rep* 2010; 11: 261-264.
38. Rhonda Kotarinos Myofascial Pelvic Pain *Curr Pain Headache Rep* (2012) 16: 433-438 DOI 10.1007/s11916-012-0277-8.
39. Weiss JM. Pelvic floor myofascial trigger points: manual therapy for interstitial cystitis and the urgency-frequency syndrome. *J Urol*. 2001; 166: 2226-2231.
40. Anderson RU, Wise D, Sawyer T, Chan C. Integration of myofascial trigger point release and paradoxical relaxation training treatment of chronic pelvic pain in men. *J Urol* 2005; 174: 155-60.
41. Simons DG. Review of enigmatic MTrPs as a common cause of enigmatic musculoskeletal pain and dysfunction. *J Electromyogr Kinesiol* 2004; 14: 95-107.
42. Sandri S, Sommariva M. SIU Guidelines on Chronic Pelvic Pain 2011.
43. Zeng Xiao-yong, Liang Chen and Ye Zhang-qun Extracorporeal shock wave treatment for non-inflammatory chronic pelvic pain syndrome: a prospective, randomized and sham-controlled study. *Chin Med J* 2012; 125(1): 114-118.
44. Montenegro ML1, Gomide LB, Mateus-Vasconcelos EL, Rosa-e-Silva JC, Candido-dos-Reis FJ, Nogueira AA, Polineto OB. Abdominal myofascial pain syndrome must be considered in the differential diagnosis of chronic pelvic pain. *Eur J Obstet Gynecol Reprod Biol*. 2009 Nov;147(1):21-4. doi: 10.1016/j.ejogrb.2009.06.025. Epub 2009 Jul 22.
45. Stacy J1, Frawley H, Powell G, Goucke R, Pavy T. Persistent pelvic pain: rising to the challenge. *Aust N Z J Obstet Gynaecol*. 2012 Dec;52(6):502-7. doi: 10.1111/j.1479-828X.2012.01473.x. Epub 2012 Sep 23.
46. Fall MI, Baranowski AP, Elneil S, Engeler D, Hughes J, Messelink EJ, Oberpenning F, de C Williams AC; European Association of Urology. EAU guidelines on chronic pelvic pain. *Eur Urol*. 2010 Jan; 57(1): 35-48. doi: 10.1016/j.eururo.2009.08.020. Epub 2009 Aug 31.
47. Zimmermann R1, Cumpas A, Hoeltl L, Janetschek G, Stenzl A, Miclea F Extracorporeal shock-wave therapy for treating chronic pelvic pain syndrome: a feasibility study and the first clinical results. *BJU Int*. 2008 Sep; 102(8): 976-80. doi: 10.1111/j.1464-410X.2008.07742.x. Epub 2008 May 28.
48. Zimmermann R1, Cumpas A, Miclea F, Janetschek G. Extracorporeal shock wave therapy for the treatment of chronic pelvic pain syndrome in males: a randomised, double-blind, placebo-controlled study. *Eur Urol*. 2009 Sep; 56(3): 418-24. doi: 10.1016/j.eururo.2009.03.043. Epub 2009 Mar 25.
49. Marszalek M, Berger I, Madersbacher S. Low-energy extracorporeal shock wave therapy for chronic pelvic pain syndrome: finally, the magic bullet? *Eur Urol*. 2009 Sep; 56(3): 425-6. doi: 10.1016/j.eururo.2009.03.075. Epub 2009 Apr 3.
50. Vahdatpour B1, Alizadeh F, Moayednia A, Emadi M, Khorami MH, Haghdani S. Efficacy of extracorporeal shock wave therapy for the treatment of chronic pelvic pain syndrome: a randomized, controlled trial *ISRN Urol*. 2013 Aug 28; 2013: 972601. doi: 10.1155/2013/972601. eCollection 2013.
51. Rompe JD, Kullmer K, Vogel J et al. Extracorporeal shock-wave therapy. Experimental basis, clinical application. *Orthopade* 1997; 26: 215-28.
52. Melzack R, Wall PD. Pain mechanisms: a new theory. *Science* 1965; 150: 971-9.
53. Wang CJ, Wang FS, Yang KD et al. Shock wave therapy induces neovascularization at the tendon-bone junction. A study in rabbits. *J Orthop Res* 2003; 21: 984-9.
54. Manganotti P, Amelio E. Long term effect of shock wave therapy on upper limb hypertonia in patients affected by stroke. *Stroke* 2005; 36: 1967-71.
55. Wess OJ. A neural model for chronic pain and pain relief by extracorporeal shock wave treatment. *Urol Res* 2008; 36: 327-34.
56. Tung CW, Cheon WC, Tong A. Novel treatment of chronic perineal pain in a woman by extracorporeal shock wave therapy: A case report and published work review. *J Obstet Gynaecol Res*. 2014 Aug 28. doi: 10.1111/jog.12487.

Correspondence to:

Andrea Meneghini, M.D.

E-mail: dott.andreameneghini@gmail.com